TRANSCELERATE BIOPHARMA INC

IN 2024, TRANSCELERATE CONTINUED TO FOCUS ON ADVANCING CLINICAL RESEARCH BY HARNESSING COLLABORATION TO ADDRESS SYSTEMIC CHALLENGES AND ACCELERATING INNOVATION. THE ORGANIZATION MADE IMPORTANT STRIDES AIMED AT BRIDGING THE GAP BETWEEN CLINICAL RESEARCH AND PATIENT CARE, MAKING VITAL TRIAL INFORMATION MORE EASILY ACCESSIBLE AND HELPING THE INDUSTRY DELIVER LIFE-SAVING MEDICINES BETTER AND FASTER.TRANSCELERATE'S PORTFOLIO OF WORK ALIGNED TO THREE CORE AREAS: 1) TRANSFORMING CONNECTIVITY, TO REDEFINE HOW RESEARCH AND CARE INTERACT; 2) INFORMATION SHARING AND REUSE, TO LEVERAGE EXISTING DATA FOR ENABLING FASTER DISCOVERIES; AND 3) INNOVATIVE TRIAL DESIGN, TO PUT PATIENTS AT THE HEART OF CLINICAL TRIALS.MEMBERSHIP GREW TO MORE THAN 20 LEADING BIOPHARMA COMPANIES, FURTHER STRENGTHENING COLLABORATIVE EFFORTS. THE ORGANIZATION LED 15 ACTIVE INITIATIVES AND COMPLETED THE YEAR WITH MORE THAN 35 TOOLS AND SOLUTIONS IN PROGRESS. SINCE ITS FOUNDING IN 2012, TRANSCELERATE HAS DEVELOPED MORE THAN 570 TOOLKITS, EMPLOYING AN APPROACH THAT COMBINES RAPID IMPROVEMENTS FOR IMMEDIATE IMPLEMENTATION WITH LONG-TERM SOLUTIONS TO TRANSFORM THE R&D ECOSYSTEM.SOME HIGHLIGHTS OF TRANSCELERATE'S PORTFOLIO OF WORK IN 2024: DIGITAL DATA FLOW INITIATIVE: MODERNIZE CLINICAL TRIALS BY ENABLING DIGITIZATION OF PROTOCOLS, AUTOMATION OF DATA FLOW AND STREAMLINING THE R&D PROCESS, REDUCING CYCLE TIMES AND IMPROVING DATA QUALITY. HISTORICAL TRIAL DATA SHARING INITIATIVE: ENABLE COMPANIES TO IMPROVE STUDY DESIGN, REDUCE PLACEBO USE AND ACCELERATE DRUG DEVELOPMENT BY RESPONSIBLY AND SECURELY SHARING AND REUSING DATA. MODERNIZING INDIVIDUAL CASE SAFETY REPORT (ICSR) MANAGEMENT INITIATIVE: SEEKS TOS TRANSFORM THE ICSR SYSTEM, WHICH WOULD REDUCE DUPLICATION, ENABLE REAL-TIME SAFETY DATA ACCESS AND ENHANCE PATIENT SAFETY THROUGH MORE EFFICIENT PROCESSING. EMBEDDED PRAGMATIC TRIALS INITIATIVE: AIMS TO FACILITATE THE ABILITY TO CONDUCT PRAGMATIC CLINICAL TRIALS BY DEVELOPING RESOURCES, PROVING FEASIBILITY AND ADDRESSING OPERATIONAL DIFFERENCES TO BETTER INTEGRATE RESEARCH INTO ROUTINE CARE. MODERNIZING CLINICAL TRIAL CONDUCT INITIATIVE: ADVANCE TRIALS BY HELPING COMPANIES ADOPT PATIENT-FRIENDLY TECHNOLOGIES LIKE TELEMEDICINE, OFFERING MORE FLEXIBILITY WHILE ENSURING PATIENT SAFETY AND DATA INTEGRITY.TRANSCELERATE COLLABORATED WITH VARIOUS ORGANIZATIONS INCLUDING THE ASSOCIATION OF CLINICAL RESEARCH ORGANIZATIONS (ACRO), THE EU PATIENT-CENTRIC CLINICAL TRIAL PLATFORMS (EU-PEARL), AND THE CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM (CDISC).THE ACRO COLLABORATION RESULTED IN CO-CREATION OF TOOLS TO SUPPORT THE IMPLEMENTATION OF THE INTERNATIONAL COUNCIL FOR HARMONIZATION'S NEW GOOD CLINICAL PRACTICE GUIDELINES AROUND THE WORLD. THROUGH THE EU-PEARL PARTNERSHIP, PROGRESS WAS MADE TO SIMPLIFY THE APPROACH TO PATIENT-FRIENDLY PLATFORM TRIALS. THE COLLABORATION WITH CDISC HELPED TO ACCELERATE THE DEVELOPMENT OF CLINICAL DATA EXCHANGE STANDARDS FOR PROTOCOL DIGITIZATION. TRANSCELERATE ENGAGED IN PRODUCTIVE DIALOGUE AND ACTION WITH GLOBAL HEALTH AUTHORITIES TO ACCELERATE THE PACE OF CHANGE THROUGH IMPLEMENTATION OF A HOLISTIC APPROACH TO ENGAGEMENT, ACTIVE PARTICIPATION WITH HEALTH AUTHORITIES AT CONFERENCES AND PUBLIC EVENTS, AND ADVANCEMENT OF KNOWLEDGE AND EDUCATION THROUGH SHARING OF INSIGHTS, LEARNINGS AND DATA. TRANSCELERATE ALSO SHARED INSIGHTS ACROSS THE R&D ECOSYSTEM: HOSTING 10 PUBLIC WEBINARS REACHING 4000+ PROFESSIONALS, PUBLISHING WHITE PAPERS TACKLING EVERYTHING FROM DECENTRALIZED TRIALS TO REAL-WORLD DATA, AND BEING FEATURED IN TOP INDUSTRY PUBLICATIONS. THE ORGANIZATION ALSO SHARED ITS VOICE AT OVER 40 LEADERSHIP-LEVEL EVENTS ACROSS 27 CITIES AND 12 COUNTRIES. THE ORGANIZATION'S WORK IN 2024 WAS AND WILL CONTINUE TO BE GEARED AROUND BUILDING A MORE EFFICIENT, PATIENT-CENTERED FUTURE FOR CLINICAL RESEARCH.